Soleno Therapeutics Inc.
Soleno Therapeutics Engages New Auditor Following Resignation of Marcum LLP
Summary
Soleno Therapeutics, Inc. announced the resignation of Marcum LLP as its independent registered public accounting firm on April 17, 2025, and the engagement of CBIZ CPAs P.C. as its new auditor, effective April 18, 2025. The resignation was approved by the Audit Committee of the Company's Board of Directors. Marcum LLP's reports on the Company's consolidated financial statements for the years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion, except for an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2024 due to a material weakness.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement